The authors of the article concluded that an extensive body of evidence from RCTs supports the new risk-based approach, with the emphasis being on the appropriate intensity of statin therapy in patients most likely to benefit. They note that the NICE guidelines on lipid modification published in 2014 have taken a similar approach.